Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 20Dulaglutide literatureObesity pillars · ObservationalHigh-impact journal2026

Clinical perspectives on pediatric weight-management programs: A nationwide look at models of care.

Pediatric obesity management shows considerable variability among clinics, highlighting the need for standardized care models to improve treatment consistency.

Read at Obesity pillarsAdd to compare

Where it sits

this study against the rest of the dulaglutide corpus
2
Preclinical
11
Observational · this one
0
Open-label
3
Randomised
4
Reviews

Summary and findings

This study assessed the current practices in pediatric weight management programs through a cross-sectional survey of 38 providers. It highlighted the variability in clinic structures and staffing, as well as the mismatch between ideal and actual follow-up times. No specific doses or treatments were evaluated.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=382026

Abstract

The authors’ words, as Obesity pillars supplied them

<h4>Background</h4>Obesity is a common, complex, and often persistent chronic disease associated with serious health and social consequences. In the United States, recent data indicates that almost 20% of children and adolescents have obesity. Management of pediatric obesity involves multidisciplinary teams, including pediatricians, pediatric specialists, dietitians, behavioral health specialists, and exercise professionals, who deliver intensive health behavior and lifestyle treatment. Prior survey data from Pediatric Endocrine Society (PES) members indicate variability in practice patterns. There is an urgent need to assess current practices across groups and use these data to establish a standard of care across institutions.<h4>Methods</h4>This is a cross-sectional survey of 38 providers who treat pediatric obesity. We report descriptive statistics (mean/median/IQR) only.<h4>Results</h4>Of 168 potential respondents, 38 completed the survey. 61% of the clinics are run within the Pediatric Endocrine division. All clinics offer pharmacotherapy, while only some offer bariatric surgery treatment. There is a wide divergence in the structure, staffing, visit frequency, intake process, and operational workflow between programs. All programs are staffed with a physician or APP, 97% with dieticians, 60% with psychologists or behavioral health therapists, and 39% with bariatric surgeons. Ideal and actual follow up times were mismatched, with programs wanting to see patients for follow up more often than they were able to.<h4>Conclusion</h4>The survey provides a detailed snapshot of current practices within pediatric weight management programs, highlighting the strengths and the substantial variability that characterize the field. While many clinics share core elements, there remains a divergence in others. These differences reflect the diverse environments in which programs operate and underscore the benefit of standardized models for delivering pediatric obesity care. This survey is an important foundation, but broader national efforts are essential to guide standardization, inform policy, and support the development of high-quality, accessible pediatric obesity care.

Background

This paper addresses the management of pediatric obesity, a chronic condition affecting nearly 20% of children and adolescents in the U.S. Existing literature indicates variability in treatment practices among providers, which can impact care quality. Understanding current practices is essential for establishing standardized care models.

Methods

The study employed a cross-sectional survey design targeting 168 potential respondents, of which 38 completed the survey. Descriptive statistics were used to summarize the data, focusing on clinic structure, staffing, and operational workflows.

Results

Of the 168 potential respondents, 38 completed the survey. The survey revealed that 61% of clinics are within the Pediatric Endocrine division, and all clinics provide pharmacotherapy. There is a notable divergence in clinic structures and staffing, with 97% employing dieticians and 39% having bariatric surgeons.

Interpretation

The findings indicate significant variability in pediatric obesity management practices, which aligns with previous reports of inconsistent treatment approaches. While the data is statistically descriptive, the clinical significance of these findings is limited due to the small sample size and lack of detailed outcome measures. The variability suggests a need for standardized care models to improve treatment consistency.

Key findings

  • 61% of clinics are run within the Pediatric Endocrine division.
  • All clinics offer pharmacotherapy, while only some offer bariatric surgery treatment.
  • 97% of programs are staffed with dieticians.
  • 60% of programs include psychologists or behavioral health therapists.
  • 39% of programs have bariatric surgeons.

Limitations

  • small n=38 providers
  • self-reported data may introduce bias
  • cross-sectional design limits causality
  • no specific treatment outcomes reported

Elsewhere in the Dulaglutide corpus

BImpact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Digestive diseases and sciences · 2026 · 8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.HumanBPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2024 · n=2033 · GLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)HumanAEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).Diabetes, obesity & metabolism · 2026 · n=573 · ETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59HumanBProjecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.Diabetes, obesity & metabolism · 2026 · 0.16 QALYs gained with icodec versus glargine U100 and degludec.BEfficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.Annals of medicine · 2026 · n=9915 · HR 0.69 for 30% eGFR decline, 95% CI 0.59-0.80, p<0.001HumanDComparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · −0.25% HbA1c mean difference vs dulaglutide, 95% CI −0.38 to −0.12, p=0.0002review